8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Entrada Therapeutics, Inc.(TRDA)Earnings, Financials & Key Ratios
TRDA•NASDAQ
Price updated Jun 19, 2026
AboutEntrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Show more
- Revenue$25M-87.9%
- EBITDA-$156M-406.3%
- Net Income-$144M-319.0%
- EPS (Diluted)-3.47-306.5%
- Gross Margin83.89%-16.1%
- EBITDA Margin-611.99%-2640.1%
- Operating Margin-613.66%-2851.4%
- Net Margin-565.48%-1916.2%
- ROE-39.13%-300.0%
TRDA Key Insights
Entrada Therapeutics, Inc. (TRDA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Profits declining 40.2% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TRDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TRDA Price & Volume
Entrada Therapeutics, Inc. (TRDA) stock price & volume — 10-year historical chart
Loading chart...
TRDA Growth Metrics
Entrada Therapeutics, Inc. (TRDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-96.67%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-770.34%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-596.09%
Return on Capital
10 Years-37.19%
5 Years-18.68%
3 Years-8.84%
Last Year-37.15%
TRDA Recent Earnings
Entrada Therapeutics, Inc. (TRDA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.95+10.4%
$1.06
Rev
$875,000-70.0%
$3M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.94+28.8%
$1.32
Rev
$1M-82.5%
$7M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.06-1.9%
$1.04
Rev
$2M-81.0%
$8M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.04-20.9%
$0.86
Rev
$2M-75.1%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.95vs $1.06+10.4% | $875,000vs $3M-70.0% |
| Q1 2026 | Feb 26, 2026 | $0.94vs $1.32+28.8% | $1Mvs $7M-82.5% |
| Q4 2025 | Nov 6, 2025 | $1.06vs $1.04-1.9% | $2Mvs $8M-81.0% |
| Q3 2025 | Aug 6, 2025 | $1.04vs $0.86-20.9% | $2Mvs $8M-75.1% |
Based on last 12 quarters of dataView full earnings history →
TRDA Peer Comparison
Entrada Therapeutics, Inc. (TRDA) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% |
Compare TRDA vs Peers
Entrada Therapeutics, Inc. (TRDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TRDA Income Statement
Entrada Therapeutics, Inc. (TRDA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 129.01M | 210.78M | 25.42M | 5.74M |
Revenue Growth % | - | - | - | - | - | 63.38% | -87.94% | -96.67% |
Cost of Goods Sold | 104K | 326K | 0 | 0 | 0 | 0 | 4.1M | 40.05M |
COGS % of Revenue | - | - | - | - | - | - | 16.11% | - |
Gross Profit | -104K▲ 0% | -326K▼ 213.5% | 0▲ 100.0% | 0▲ 0% | 129.01M▲ 0% | 210.78M▲ 63.4% | 21.32M▼ 89.9% | -34.31M▲ 0% |
Gross Margin % | - | - | - | - | 100% | 100% | 83.89% | -598.01% |
Gross Profit Growth % | - | -213.46% | 100% | - | - | 63.38% | -89.88% | - |
Operating Expenses | 11.82M | 26.34M | 51.13M | 97.25M | 132.18M | 163.77M | 177.32M | 144.1M |
OpEx % of Revenue | - | - | - | - | 102.45% | 77.7% | 697.55% | - |
Selling, General & Admin | 3.61M | 5.24M | 15.2M | 30.64M | 32.29M | 38.47M | 41.05M | 40.9M |
SG&A % of Revenue | - | - | - | - | 25.03% | 18.25% | 161.48% | - |
Research & Development | 8.22M | 21.1M | 35.93M | 66.61M | 99.88M | 125.31M | 142.27M | 143.25M |
R&D % of Revenue | - | - | - | - | 77.42% | 59.45% | 559.65% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -6M | -2.69M |
Operating Income | -11.82M▲ 0% | -26.67M▼ 125.5% | -51.13M▼ 91.7% | -97.25M▼ 90.2% | -3.16M▲ 96.7% | 47.01M▲ 1586.7% | -156M▼ 431.8% | -178.41M▲ 0% |
Operating Margin % | - | - | - | - | -2.45% | 22.3% | -613.66% | -3109.29% |
Operating Income Growth % | - | -125.53% | -91.72% | -90.21% | 96.75% | 1586.75% | -431.83% | - |
EBITDA | -11.72M | -26.34M | -50.01M | -95.35M | -321K | 50.78M | -155.57M | -178.13M |
EBITDA Margin % | - | - | - | - | -0.25% | 24.09% | -611.99% | -3104.34% |
EBITDA Growth % | - | -124.75% | -89.86% | -90.67% | 99.66% | 15920.56% | -406.34% | -2356.77% |
D&A (Non-Cash Add-back) | 104K | 326K | 1.12M | 1.9M | 2.84M | 3.77M | 425K | 284K |
EBIT | -11.82M | -26.52M | -51.13M | -97.25M | -3.16M | 47.01M | -142.83M | -171.7M |
Net Interest Income | 0 | 0 | 0 | 0 | 15.22M | 19.47M | 0 | 3.92M |
Interest Income | 0 | 0 | 0 | 2.63M | 15.22M | 19.47M | 0 | 3.92M |
Interest Expense | 0 | 0 | 0 | 2.63M | 0 | 0 | 0 | 0 |
Other Income/Expense | 6.72M | 144K | -31K | 2.63M | 15.22M | 19.47M | 13.17M | 13.26M |
Pretax Income | -5.1M▲ 0% | -26.52M▼ 420.1% | -51.16M▼ 92.9% | -94.62M▼ 84.9% | 12.06M▲ 112.7% | 66.48M▲ 451.5% | -142.83M▼ 314.8% | -165.16M▲ 0% |
Pretax Margin % | - | - | - | - | 9.34% | 31.54% | -561.84% | -2878.29% |
Income Tax | 0 | 0 | 0 | 0 | 18.74M | 859K | 924K | 962K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 155.45% | 1.29% | -0.65% | -0.58% |
Net Income | -4.65M▲ 0% | -26.52M▼ 470.5% | -51.16M▼ 92.9% | -94.62M▼ 84.9% | -6.68M▲ 92.9% | 65.63M▲ 1081.7% | -143.75M▼ 319.0% | -166.12M▲ 0% |
Net Margin % | - | - | - | - | -5.18% | 31.13% | -565.48% | -2895.05% |
Net Income Growth % | - | -470.51% | -92.88% | -84.95% | 92.93% | 1081.69% | -319.04% | -770.34% |
Net Income (Continuing) | -5.1M | -26.52M | -51.16M | -94.62M | -6.68M | 65.63M | -143.75M | -166.12M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.44▲ 0% | -0.84▲ 81.1% | -1.60▼ 90.5% | -2.79▼ 74.4% | -0.20▲ 92.8% | 1.68▲ 940.0% | -3.47▼ 306.5% | -3.97▲ 0% |
EPS Growth % | - | 81.08% | -90.48% | -74.38% | 92.83% | 940% | -306.55% | -596.09% |
EPS (Basic) | -4.44 | -0.84 | -1.60 | -2.79 | -0.20 | 1.76 | -3.47 | - |
Diluted Shares Outstanding | 1.05M | 31.25M | 31.22M | 31.29M | 33.05M | 39M | 41.37M | 41.84M |
Basic Shares Outstanding | 1.05M | 31.25M | 31.22M | 31.29M | 33.05M | 37.31M | 41.37M | 41.84M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TRDA Balance Sheet
Entrada Therapeutics, Inc. (TRDA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 17.44M | 39.95M | 298.7M | 209.88M | 369.77M | 440.04M | 306.25M | 266.87M |
Cash & Short-Term Investments | 16.84M | 39.05M | 291.06M | 188.71M | 351.97M | 420M | 295.7M | 254.86M |
Cash Only | 16.84M | 39.05M | 291.06M | 45.16M | 67.6M | 101.21M | 90.39M | 76.44M |
Short-Term Investments | 0 | 0 | 0 | 143.56M | 284.37M | 318.79M | 205.3M | 178.41M |
Accounts Receivable | 0 | 0 | 0 | 0 | 5.88M | 3.68M | 0 | 0 |
Days Sales Outstanding | - | - | - | - | 16.63 | 6.37 | - | 69.59 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 21.16M | 11.92M | 16.36M | 10.55M | 12.01M |
Total Non-Current Assets | 801K | 3.58M | 7.13M | 42.18M | 99.42M | 86.28M | 71.13M | 68.65M |
Property, Plant & Equipment | 801K | 3.04M | 6.26M | 33.02M | 92.68M | 82.05M | 67.76M | 65.26M |
Fixed Asset Turnover | - | - | - | - | 1.39x | 2.57x | 0.38x | 0.08x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.95M |
Other Non-Current Assets | 0 | 541K | 872K | 9.16M | 6.74M | 4.23M | 3.36M | 3.38M |
Total Assets | 18.24M▲ 0% | 43.53M▲ 138.7% | 305.83M▲ 602.6% | 252.06M▼ 17.6% | 469.19M▲ 86.1% | 526.32M▲ 12.2% | 377.38M▼ 28.3% | 335.52M▲ 0% |
Asset Turnover | - | - | - | - | 0.27x | 0.40x | 0.07x | 0.01x |
Asset Growth % | - | 138.66% | 602.63% | -17.58% | 86.15% | 12.18% | -28.3% | -107.76% |
Total Current Liabilities | 1.92M | 3.36M | 6.72M | 21.97M | 158.8M | 39.48M | 24.45M | 19.2M |
Accounts Payable | 710K | 1.6M | 706K | 5.99M | 3.28M | 4.26M | 2.29M | 2.93M |
Days Payables Outstanding | 2.49K | 1.79K | - | - | - | - | 203.98 | 23.33 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 4.14M | 4.28M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 132.26M | 13.65M | 342K | 1.64M |
Other Current Liabilities | 937K | 1.6M | 4.56M | 5.49M | 7.66M | 8.43M | 17.68M | 11.73M |
Current Ratio | 9.08x | 11.89x | 44.46x | 9.55x | 2.33x | 11.15x | 12.53x | 13.90x |
Quick Ratio | 9.08x | 11.89x | 44.46x | 9.55x | 2.33x | 11.15x | 12.53x | 13.90x |
Cash Conversion Cycle | - | - | - | - | - | - | - | 46.26 |
Total Non-Current Liabilities | 31.84M | 81.66M | 396K | 17.53M | 68.04M | 58.16M | 46.79M | 45.47M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 46.79M | 45.47M |
Capital Lease Obligations | 0 | 0 | 0 | 17.53M | 60.32M | 51.65M | 0 | 97.33M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 31.84M | 81.66M | 396K | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 33.76M | 85.02M | 7.12M | 39.5M | 226.83M | 97.64M | 71.25M | 64.66M |
Total Debt | 0 | 0 | 0 | 25.94M | 68.23M | 59.21M | 50.93M | 49.75M |
Net Debt | -16.84M | -39.05M | -291.06M | -19.22M | 628K | -42M | -39.46M | -26.69M |
Debt / Equity | - | - | - | 0.12x | 0.28x | 0.14x | 0.17x | 0.18x |
Debt / EBITDA | - | - | - | - | - | 1.17x | - | -0.28x |
Net Debt / EBITDA | - | - | - | - | - | -0.83x | - | 0.15x |
Interest Coverage | - | - | - | -36.95x | - | - | - | - |
Total Equity | -15.52M▲ 0% | -41.49M▼ 167.4% | 298.72M▲ 820.0% | 212.55M▼ 28.8% | 242.36M▲ 14.0% | 428.68M▲ 76.9% | 306.13M▼ 28.6% | 270.85M▲ 0% |
Equity Growth % | - | -167.37% | 819.98% | -28.84% | 14.02% | 76.88% | -28.59% | -94.75% |
Book Value per Share | -14.81 | -1.33 | 9.57 | 6.79 | 7.33 | 10.99 | 7.40 | 6.47 |
Total Shareholders' Equity | -15.52M | -41.49M | 298.72M | 212.55M | 242.36M | 428.68M | 306.13M | 270.85M |
Common Stock | 0 | 0 | 3K | 3K | 3K | 4K | 4K | 4K |
Retained Earnings | -15.99M | -42.51M | -93.67M | -188.28M | -194.97M | -129.34M | -273.09M | -312.81M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -2.06M | 195K | -43K | 652K | 246K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TRDA Cash Flow Statement
Entrada Therapeutics, Inc. (TRDA) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.8M | -25.57M | -50.86M | -93.79M | 139.8M | -41.56M | -128.51M | -131.7M |
Operating CF Margin % | - | - | - | - | 108.36% | -19.72% | -505.53% | - |
Operating CF Growth % | - | -136.74% | -98.91% | -84.39% | 249.07% | -129.73% | -209.24% | -200.88% |
Net Income | -5.1M | -26.52M | -51.16M | -94.62M | -6.68M | 65.63M | -143.75M | -166.12M |
Depreciation & Amortization | 104K | 326K | 1.12M | 1.9M | 2.84M | 3.77M | 425K | 254K |
Stock-Based Compensation | 294K | 325K | 2.53M | 9.89M | 13.11M | 17.91M | 19.61M | 9.41M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -6.27M | 20K | 74K | 151K | -5.78M | -10.02M | 0 | 10.68M |
Working Capital Changes | 174K | 282K | -3.42M | -11.11M | 136.31M | -118.85M | -4.8M | 14.08M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 2.2M | 2.5M | 1.26M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 367K | 631K | -715K | 5.29M | -2.81M | 991K | -1.8M | 752K |
Cash from Investing | -630K | -2.32M | -4.58M | -148.65M | -138.4M | -27.8M | 116.81M | 139.01M |
Capital Expenditures | -630K | -2.32M | -4.58M | -2.89M | -5.61M | -3.16M | -1.04M | 59K |
CapEx % of Revenue | - | - | - | - | 4.35% | 1.5% | 4.09% | 1.03% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 38K | 50.09M | 307.46M | 479K | 21.04M | 102.96M | 887K | 637K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 38K | 49.84M | 306.52M | 479K | 19.41M | 99.61M | 887K | 637K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 247K | 939K | 0 | 1.63M | 3.36M | 0 | 0 |
Net Change in Cash | 16.84M▲ 0% | 22.2M▲ 31.8% | 252.02M▲ 1035.2% | -245.91M▼ 197.6% | 22.45M▲ 109.1% | 33.61M▲ 49.7% | -10.82M▼ 132.2% | 7.95M▲ 0% |
Free Cash Flow | -11.43M▲ 0% | -27.89M▼ 144.0% | -55.44M▼ 98.8% | -96.67M▼ 74.4% | 134.19M▲ 238.8% | -44.72M▼ 133.3% | -129.55M▼ 189.7% | -131.64M▲ 0% |
FCF Margin % | - | - | - | - | 104.01% | -21.21% | -509.63% | -2294.2% |
FCF Growth % | - | -143.97% | -98.8% | -74.37% | 238.81% | -133.32% | -189.73% | -126.93% |
FCF per Share | -10.91 | -0.89 | -1.78 | -3.09 | 4.06 | -1.15 | -3.13 | -3.15 |
FCF Conversion (FCF/Net Income) | 2.32x | 0.96x | 0.99x | 0.99x | -20.91x | -0.63x | 0.89x | 0.79x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 14.72M | 4.62M | 0 | 0 |
TRDA Key Ratios
Entrada Therapeutics, Inc. (TRDA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -39.78% | -37.01% | -2.94% | 19.56% | -39.13% | -51.22% |
Return on Invested Capital (ROIC) | - | - | -72.58% | -1.09% | 11.2% | -35.82% | -45.65% |
Gross Margin | - | - | - | 100% | 100% | 83.89% | -598.01% |
Net Margin | - | - | - | -5.18% | 31.13% | -565.48% | -2895.05% |
Debt / Equity | - | - | 0.12x | 0.28x | 0.14x | 0.17x | 0.18x |
Interest Coverage | - | - | -36.95x | - | - | - | - |
FCF Conversion | 0.96x | 0.99x | 0.99x | -20.91x | -0.63x | 0.89x | 0.79x |
Revenue Growth | - | - | - | - | 63.38% | -87.94% | -96.67% |
Related:TRDA Dividend History·TRDA Revenue History·TRDA Price History·TRDA P/E History·TRDA Financial Ratios·TRDA Institutional Holders
TRDA SEC Filings & Documents
Entrada Therapeutics, Inc. (TRDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TRDA Frequently Asked Questions
Entrada Therapeutics, Inc. (TRDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Entrada Therapeutics, Inc. (TRDA) reported $5.7M in revenue for fiscal year 2025.
Entrada Therapeutics, Inc. (TRDA) saw revenue decline by 87.9% over the past year.
Entrada Therapeutics, Inc. (TRDA) reported a net loss of $166.1M for fiscal year 2025.
Dividend & Returns
Entrada Therapeutics, Inc. (TRDA) has a return on equity (ROE) of -39.1%. Negative ROE indicates the company is unprofitable.
Entrada Therapeutics, Inc. (TRDA) had negative free cash flow of $131.6M in fiscal year 2025, likely due to heavy capital investments.